Sientra (SIEN) Given Coverage Optimism Score of 0.08
News stories about Sientra (NASDAQ:SIEN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sientra earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 47.1691903302577 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- The global nasal implant market is projected to register a significant CAGR of 6.0% according to new research report (whatech.com)
- Sientra’s (SIEN) CEO Jeff Nugent on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- BRIEF-Sientra’s total net sales for Q3 2017 were $9.8 million (reuters.com)
- Sientra, Inc. to Host Earnings Call (finance.yahoo.com)
- Sientra Reports Third Quarter 2017 Financial Results (finance.yahoo.com)
Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Sientra from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price target (up from $11.00) on shares of Sientra in a research note on Wednesday, September 27th. Canaccord Genuity reiterated a “buy” rating and issued a $14.00 price target on shares of Sientra in a research note on Sunday, October 8th. Lake Street Capital reiterated a “buy” rating and issued a $15.00 price target (up from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. Finally, William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Sientra currently has an average rating of “Hold” and an average target price of $13.75.
Shares of Sientra (NASDAQ:SIEN) traded down $0.18 during trading on Monday, hitting $13.50. 106,500 shares of the company traded hands, compared to its average volume of 156,670. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.87 and a quick ratio of 1.92. Sientra has a 52 week low of $7.20 and a 52 week high of $16.68.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.06). The business had revenue of $9.80 million during the quarter, compared to the consensus estimate of $10.54 million. Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The firm’s revenue was up 50.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.55) earnings per share. equities research analysts expect that Sientra will post -3.14 earnings per share for the current fiscal year.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.